Healthcare provider profile · identity verified

Alisa Takeda, D.O.

Internal Medicine · OAKLAND, CA · NPI 1053738021

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	397	149
Amlodipine Besylate	Amlodipine Besylate	177	67
Losartan Potassium	Losartan Potassium	162	57
Metoprolol Succinate	Metoprolol Succinate	132	44
Famotidine	Famotidine	128	60
Metformin Hcl	Metformin Hcl	124	37
Jardiance	Empagliflozin	112	32
Triamcinolone Acetonide	Triamcinolone Acetonide	100	55
Lisinopril	Lisinopril	94	35
Gabapentin	Gabapentin	92	47
Fluticasone Propionate	Fluticasone Propionate	89	42
Albuterol Sulfate Hfa	Albuterol Sulfate	86	32
Tamsulosin Hcl	Tamsulosin Hcl	85	31
Hydrocortisone	Hydrocortisone	68	34
Lidocaine	Lidocaine	63	30
Glipizide	Glipizide	53	17
Simvastatin	Simvastatin	47	11
Alendronate Sodium	Alendronate Sodium	45	16
Januvia	Sitagliptin Phosphate	43	15
Hydrochlorothiazide	Hydrochlorothiazide	39	17
Metformin Hcl Er	Metformin Hcl	38	13
Levothyroxine Sodium	Levothyroxine Sodium	37	12
Montelukast Sodium	Montelukast Sodium	35	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	35	20
Hydralazine Hcl	Hydralazine Hcl	34	11
Xarelto	Rivaroxaban	33	11
Allopurinol	Allopurinol	32	12
Furosemide	Furosemide	32	14
Pregabalin	Pregabalin	32	12
Mirtazapine	Mirtazapine	31	14
Trazodone Hcl	Trazodone Hcl	31	20
Clopidogrel	Clopidogrel Bisulfate	29	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	29	suppressed
Donepezil Hcl	Donepezil Hcl	28	suppressed
Finasteride	Finasteride	28	suppressed
Meloxicam	Meloxicam	28	19
Azelastine Hcl	Azelastine Hcl	26	15
Carvedilol	Carvedilol	26	11
Omeprazole	Omeprazole	26	12
Rybelsus	Semaglutide	26	13
Colchicine	Colchicine	24	11
Eliquis	Apixaban	24	suppressed
Baclofen	Baclofen	23	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	23	12
Quetiapine Fumarate	Quetiapine Fumarate	23	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	23	suppressed
Diclofenac Sodium	Diclofenac Sodium	21	13
Advair Hfa	Fluticasone Propion/Salmeterol	20	suppressed
Clonazepam	Clonazepam	20	suppressed
Ozempic	Semaglutide	20	suppressed
Atenolol	Atenolol	18	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Incruse Ellipta	Umeclidinium Bromide	18	suppressed
Meclizine Hcl	Meclizine Hcl	18	12
Pravastatin Sodium	Pravastatin Sodium	18	suppressed
Sertraline Hcl	Sertraline Hcl	18	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	17	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	17	suppressed
Memantine Hcl	Memantine Hcl	17	suppressed
Nifedipine Er	Nifedipine	17	suppressed
Tradjenta	Linagliptin	17	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	16	11
Metoprolol Tartrate	Metoprolol Tartrate	16	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	16	suppressed
Prednisone	Prednisone	16	13
Breo Ellipta	Fluticasone/Vilanterol	15	suppressed
Ibuprofen	Ibuprofen	15	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Lidocaine-Prilocaine	Lidocaine/Prilocaine	15	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	11
Chlorhexidine Gluconate	Chlorhexidine Gluconate	14	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Promethazine Hcl	Promethazine Hcl	14	suppressed
Tizanidine Hcl	Tizanidine Hcl	14	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	13	12
Mupirocin	Mupirocin	13	12
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Valsartan	Valsartan	13	suppressed
Vascepa	Icosapent Ethyl	13	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Ventolin Hfa	Albuterol Sulfate	12	suppressed
Acarbose	Acarbose	11	suppressed
Duloxetine Hcl	Duloxetine Hcl	11	suppressed
Lovastatin	Lovastatin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error